Corrigendum to "Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: effects on weight loss and safety in adults with overweight or obesity" [Mol Metab 78 (2023) 101801].

ABSTRACT:

SUBMITTER: Friedrichsen MH 

PROVIDER: S-EPMC11415713 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature